#	Pagina
attuale pagina	/open-h2020/projects/199722/index.html

Opendata, web and dolomites

TAT-CF SIGNED

Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TAT-CF project word cloud

Explore the words cloud of the TAT-CF project. It provides you a very rough idea of what is the project "TAT-CF" about.

quantitative translational therapeutic 2020 unexplored validate overcomes mutation treatment channel searching living cf instead truly people plan patients limitation treatments missing small models radically clinical respect strategies shift cystic function transport originates innovative rare permeation chloride protein permeable compound bicarbonate therapy options transmembrane team complete qualifies molecules anion ready rmultidisciplinary disease synthesis animal fibrosis preclinical qualified regardless defective advancing cftr assembled applicable said compounds 200 diseases therapies validation anions least harbor drugs irdirc replacing paradigm cure

Project "TAT-CF" data sheet

The following table provides information about the project.

Coordinator	UNIVERSIDAD DE BURGOS Organization address address: HOSPITAL DEL REY city: BURGOS postcode: 9001 website: www.ubu.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.tat-cf.eu
Total cost	4˙591˙287 €
EC max contribution	4˙591˙287 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-01-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSIDAD DE BURGOS UNIVERSIDAD DE BURGOS Organization address address: HOSPITAL DEL REY city: BURGOS postcode: 9001 website: www.ubu.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BURGOS)	coordinator	665˙563.00
2	AVIDIN KUTATO, FEJLESZTO ES KERESKEDELMI KFT AVIDIN KUTATO, FEJLESZTO ES KERESKEDELMI KFT Organization address address: ALSO KIKOTO SOR 11 city: SZEGED postcode: 6726 website: www.avidinbiotech.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	HU (SZEGED)	participant	732˙875.00
3	CONSIGLIO NAZIONALE DELLE RICERCHE CONSIGLIO NAZIONALE DELLE RICERCHE Organization address address: PIAZZALE ALDO MORO 7 city: ROMA postcode: 185 website: www.cnr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	610˙273.00
4	BIOKERALTY RESEARCH INSTITUTE AIE BIOKERALTY RESEARCH INSTITUTE AIE Organization address address: ENTIDAD ARCAUTE, 005, ARCAUTE city: ARCAUTE ALAVA postcode: 1192 website: www.grupo-praxis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (ARCAUTE ALAVA)	participant	591˙875.00
5	BIONEER A/S BIONEER A/S Organization address address: KOGLE ALLE 2 city: HOERSHOLM postcode: 2970 website: www.bioneer.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HOERSHOLM)	participant	557˙375.00
6	STEINBEIS INNOVATION GGMBH STEINBEIS INNOVATION GGMBH Organization address address: WILLI BLEICHER STRASSE 19 city: STUTTGART postcode: 70174 website: http://www.stw.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (STUTTGART)	participant	523˙953.00
7	AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 website: http://www.csic.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	519˙368.00
8	ISTITUTO GIANNINA GASLINI ISTITUTO GIANNINA GASLINI Organization address address: VIA GEROLAMO GASLINI 5 city: GENOVA postcode: 16147 website: www.gaslini.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (GENOVA)	participant	390˙002.00

Map

Project objective

This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF treatment by replacing the missing CFTR anion permeation activity. This represents an unexplored path in the treatment of CF and a paradigm shift with respect to current strategies searching for a cure for CF. Instead of focusing on the development of mutation-specific treatments, we plan to develop a therapy applicable to CF patients, regardless of the type of mutation they harbor. Thus, this therapeutic approach overcomes the limitation of current mutation-specific treatments and is applicable to CF patients in general. To achieve this goal we have set up a comprehensive program to validate a research concept and complete the preclinical development of a new lead compound, making it ready for early clinical development. A rmultidisciplinary team of qualified researchers have been assembled to bring to conclusion a truly translational project from the synthesis of new compounds to validation on animal models. Cystic Fibrosis affects more people than any other rare disease. Therefore, it could be said, at least in quantitative terms, that CF qualifies as the main target of the topic. This project aims to complete the preclinical development of novel, innovative drugs based on a radically new concept in Cystic Fibrosis therapies. This result fully addresses the expected impact set out in the work programme of advancing the development of new therapeutic options for patients living with rare diseases as well as contributing to reach the IRDiRC objective to deliver 200 new therapies for rare diseases by 2020.

Deliverables

List of deliverables.
Lung epithelial cells from F508del patients	Documents, reports	2019-07-26 14:38:12
Biophysical and pharmacological characterisation of the anionophores	Documents, reports	2019-07-26 14:38:13
Project Website	Websites, patent fillings, videos etc.	2019-07-26 14:38:13
Anionophores in F508del and G551D mouse models	Documents, reports	2019-07-26 14:38:13
Physiology of normal and cystic fibrosis bronchial epithelium; Imaging assay	Documents, reports	2019-07-26 14:38:12
iPS cells from G551D patients	Documents, reports	2019-07-26 14:38:12
iPS cells from F508del patients	Documents, reports	2019-07-26 14:38:12
Intestinal organoids from G551D patients	Documents, reports	2019-07-26 14:38:12
Calu-3 mutant CFTR F508del and G551D cells	Documents, reports	2019-07-26 14:38:13
Intestinal organoids from F508del patients	Documents, reports	2019-07-26 14:38:12
pH-insensitive Cl- sensor assay	Documents, reports	2019-07-26 14:38:13
Lung epithelial cells from G551D patients	Documents, reports	2019-07-26 14:38:13
Correlation of anion transport activity with mucin release in Calu-3 CFTR wt and mutant sensor cell lines	Documents, reports	2019-07-26 14:38:12

Take a look to the deliverables list in detail: detailed list of TAT-CF deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Aarne Fleischer, IvÃ¡n M. Lorenzo, Esther Palomino, Trond Aasen, Fernando GÃ³mez, Miguel Servera, VÃctor J. Asensio, VÃctor GÃ¡lvez, Juan Carlos IzpisÃºa-Belmonte, Daniel Bachiller Generation of two induced pluripotent stem cell (iPSC) lines from p.F508del Cystic Fibrosis patients published pages: 1-5, ISSN: 1873-5061, DOI: 10.1016/j.scr.2018.03.004	Stem Cell Research 29	2019-07-26
2018	Ãngel del Pozo, Roberto Quesada, Manfred Frey 4th TAT-CF Newsletter published pages: , ISSN: , DOI:		2019-07-26
2018	Ãngel del Pozo, Roberto Quesada, Oscar Moran, Emanuela Caci, Manfred Frey, Daniel Bachiller, Anette Mullertz, Laszlo Puskas 6th TAT-CF Newsletter published pages: , ISSN: , DOI:		2019-07-26
2018	Ãngel del Pozo, Roberto Quesada 5th TAT-CF Newsletter published pages: , ISSN: , DOI:		2019-07-26
2018	Ãngel del Pozo, Roberto Quesada, Oscar Moran, Emanuela Caci 3rd TAT-CF Newsletter published pages: , ISSN: , DOI:		2019-07-26
2018	Elsa Hernando, Valeria Capurro, Claudia Cossu, Michele Fiore, MarÃa GarcÃa-Valverde, Vanessa Soto-Cerrato, Ricardo PÃ©rez-TomÃ¡s, Oscar Moran, Olga Zegarra-Moran, Roberto Quesada Small molecule anionophores promote transmembrane anion permeation matching CFTR activity published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-20708-3	Scientific Reports 8/1	2019-07-26
2018	Claudia Cossu, Michele Fiore, Debora Baroni, Valeria Capurro, Emanuela Caci, Maria Garcia-Valverde, Roberto Quesada, Oscar Moran Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2018.00852	Frontiers in Pharmacology 9	2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TAT-CF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TAT-CF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials